Teva Pharmaceutical Industries Limited (TEVA) Stock Score, Valuation & Financial Research
Teva Pharmaceutical Industries Limited is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for TEVA
Teva Pharmaceutical Industries Limited currently has a Wall Street Score of 27/100. The stored market price is $37.09. Its financial score is 24/100. Its valuation score is 16/100. These figures are a research snapshot, not a buy or sell recommendation.
What Teva Pharmaceutical Industries Limited does
Teva Pharmaceutical Industries Limited functions as a global pharmaceutical enterprise, involved in the conception, manufacturing, marketing, and provision of a broad spectrum of generic, specialty, and biopharmaceutical products throughout North America, Europe, and various international markets. The company's diverse product range includes sterile items, hormones, potent drugs, and cytotoxic agents, available in numerous forms like tablets, capsules, injectable solutions, inhalable preparations, liquids, transdermal patches, topical ointments, and creams. Additionally, Teva develops, produces, and sells active pharmaceutical ingredients (APIs). The firm prioritizes several key therapeutic domains: central nervous system disorders, pain management, respiratory ailments, and oncology. In the central nervous system sector, prominent products include Copaxone, intended for relapsing forms
TEVA financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $37.09
- Market capitalization:
- $43.20B
- Revenue:
- $17.35B
- Net income:
- $1.56B
- Free cash flow:
- $1.15B
- Cash:
- $3.74B
- Total debt:
- $16.91B
- EPS:
- 1.23
- P/E ratio:
- 30.2x
- Financial score:
- 24/100
- Valuation score:
- 16/100
- Revenue score:
- 17/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $1.15B, showing positive cash generation.
- The balance sheet shows $3.74B of cash versus $16.91B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 16/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TEVA
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.